Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, today announced the closing of a $102 million Series C financing. The round was led by Biotechnology Value Fund (BVF) and Redmile Group with participation from Wellington Management Company, Bain Capital Life Sciences, funds managed by Janus Henderson Investors and BlackRock, Rock Springs Capital and a large US-based, healthcare-focused fund. Existing investors also participated in the round.
Who to call at Kymera Therapeutics, and when
A new round usually means Kymera Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Kymera Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Kymera Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Kymera Therapeutics. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Kymera Therapeutics
Location
Watertown, Massachusetts, United States
About
Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Kymera Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
WatertownBiotechnologyTherapeuticsPharmaceuticalBiopharma